Oncology · NSCLCTrial Updateclinicalmid-term

Pharmacogenomics Trial for Alectinib in NSCLC Examines SNP Impact

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 12:32:21 AM

Assessment confidence: 90% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This trial explores the pharmacogenomic factors influencing Alectinib's efficacy and side effects, which could lead to personalized treatment strategies in NSCLC. The findings may significantly impact prescribing practices and competitive positioning in the oncology market. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 8 ranked evidence items (7 high-relevance).

Strategic Assessment

The strongest clinical anchor is Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms (ClinicalTrials.gov), sub-indication match (lung cancer); mechanism alignment (alk). In lung cancer, 0 regulatory and 4 competitive items passed relevance filtering for Alectinib. If the trial results support personalized treatment approaches, Alectinib could gain a stronger market position, potentially increasing revenue and market share against competitors.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sub-indication match (lung cancer); mechanism alignment (alk). Secondary pressure from Phase III Trial of Atezolizumab Post-Surgery for Stage I NSCLC Shows Promise.

Regulatory Outlook

Regulatory risk is concentrated around Outcomes from this trial could lead to updates in labeling and treatment guidelines, affecting compliance and approval processes for Alectinib..

Key Risks

Elevated medium regulatory exposure for Alectinib could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If the trial results support personalized treatment approaches, Alectinib could gain a stronger market position, potentially increasing revenue and market share against competitors.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Upside for Alectinib may improve if Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
The outcomes of this trial for future development strategies and potential labeling updates for Alectinib.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent changes in treatment guidelines or Alectinib's market positioning based on pharmacogenomic findings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Regulatory pathway relevance (label); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Mechanism alignment (ALK)
FDA document
View source
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Mechanism alignment (ALK)
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (nsclc)
FDA document
View source
Trial of Management of Chronic Tinnitus by Sound Therapy and Cognitive Behavioral Therapy
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study of the Impact of Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Endometrial Cavity After Conservative Management of PAS Patients by Hysteroscopy
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Mechanism alignment (ALK)
Phase III Trial of Atezolizumab Post-Surgery for Stage I NSCLC Shows Promise
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Entity match (nsclc)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Entity match (nsclc)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Entity match (nsclc)

Budget impact of implementing AI-enabled chest X-ray based incidental pulmonary nodule detection for early lung cancer diagnosis: models from Colombia, Costa Rica, Mexico, Thailand and Vietnam.
PubMedmedium relevance
Sub-indication match (lung cancer)
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Alectinib
CYP4503A4
NSCLC

Commercial impact

medium

If the trial results support personalized treatment approaches, Alectinib could gain a stronger market position, potentially increasing revenue and market share against competitors.

Regulatory impact

medium

Outcomes from this trial could lead to updates in labeling and treatment guidelines, affecting compliance and approval processes for Alectinib.

What to watch

Monitor trial results and any subsequent changes in treatment guidelines or Alectinib's market positioning based on pharmacogenomic findings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.